Group 1: IPO Performance - 2025 has been a strong year for IPOs in the United States, with notable debuts from companies like Coreweave, Figma, and Circle [1] - A model portfolio of all H1 2025 US IPOs returned 75.9% through June, significantly outperforming the S&P 500's 4.9% return, driven by large deals in AI and fintech [1] Group 2: Medline Overview - Medline, founded in 1966, is a major healthcare and medical-surgical products manufacturer and distributor, operating in two segments: proprietary medical products and supply chain solutions [3] - Medline is the largest provider of medical-surgical and supply chain solutions globally, with a catalog of over 335,000 products and 69 distribution centers [6] Group 3: Medline IPO Details - Medline upsized its IPO, selling 216 million shares at $29 each, raising $6.26 billion, compared to the initial plan of 179 million shares at a price range of $26 to $30 per share [4] - The shares debuted with a 41% rally from their issue price, and the proceeds are intended for debt reduction and general corporate purposes [4] Group 4: Financial Performance - Medline's revenues have grown at a CAGR of 18% since its inception, with sales increasing from $21.45 billion in 2022 to $23.23 billion in 2023, and $25.51 billion in 2024 [7] - For the first six months of 2025, Medline reported net sales of $13.53 billion [7]
Should You Buy Medline Stock After the MDLN IPO?